electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.0433 USD -1.33% Market Closed
Market Cap: 105.1m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

electroCore, Inc.
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Other Equity
$177k
CAGR 3-Years
N/A
CAGR 5-Years
12%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Other Equity
$25.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Equity
-$128m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Other Equity
-$545m
CAGR 3-Years
13%
CAGR 5-Years
0%
CAGR 10-Years
-21%
Abbott Laboratories
NYSE:ABT
Other Equity
-$7.8B
CAGR 3-Years
5%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Equity
$23.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
37%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
104.4m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.4922 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Other Equity?
Other Equity
177k USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Other Equity amounts to 177k USD.

What is electroCore, Inc.'s Other Equity growth rate?
Other Equity CAGR 5Y
12%

Back to Top